Recombinant protein of the receptor binding domain (RBD), Mutant (N439K) of SARS-CoV-2 (COVID-2019) Spike S1 from Wuhan pneumonia virus with C-terminal His-Tag. The N439K mutation, lineage B.1.141/B.1.258 (Scotland/UK)), is known as the second common mutation in the RBD of SARS-CoV-2 and binds with high affinity to human ACE2 receptor. The mutation may result in immune escape from a panel of neutralizing monoclonal antibodies and polyclonal sera of persons recovered from infection.
Product Name: SARS-CoV-2 (COVID-19) Spike S1 Protein (RBD, Mutant (N439K))
Sequence without tags (AA 319-541): RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYA DSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAG STPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF
Expression Host: human, HEK293
Formulation: PBS, pH 7,4
Format: Liquid, stored and shipped at -80°C
Purity: > 70% as determined by SDS-PAGE
The spike (S) glycoprotein of coronaviruses is essential for binding of the virus to the host cell at the beginning of the infection process. The target protein is also a major immunogen and a possible target for entry inhibitors. The SARS-CoV-2 spike (S) protein is a large type I transmembrane protein composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain (RBD) responsible for binding to the host cell receptor angiotensin-converting enzyme 2 (ACE2). Several mutants of the spike protein are known. The N439K mutation is known as the second most common mutation in the receptor binding domain and results in increased ACE2 affinity. This mutation seems to have no impact on the clinical spectrum of disease with slightly higher viral loads in vivo. However, the N439K mutants bind to the human ACE2 receptor with two-fold greater affinity and are may be resistant to some neutralising monoclonal antibodies that are used in treatments against COVID-19.